HCW Biologics is advancing a pipeline of potentially transformative immunotherapy product candidates for the treatment of inflammaging and age-related diseases. Our initial clinical trials are in the oncology arena, an age-related disease with a high unmet need. A pair of Phase 2 clinical trials are now underway for a cell-based therapy treatment for acute myeloid leukemia (AML), through our licensee, Wugen Inc. We plan to initiate clinical trials by the end of 2021 for our lead product candidate, HCW9218, which is an injectable immunotherapeutic, in solid tumors such as pancreatic cancer, breast cancer and ovarian cancer.
Our lead product candidates are undergoing clinical development in several indications, including solid and hematologic tumors, such as acute myeloid leukemia (AML), pancreatic cancer, breast cancer and ovarian cancer. Once the safe dose level and regimen of the lead product candidates are defined in the oncology trials, HCW will expand into clinical trials for treatments of other age-related pathologies, including fibrotic diseases (e.g., IPF, COPD, and NASH) and metabolic diseases (e.g., type 2 diabetes and atherosclerosis).